ArticleMalaria journal2025
Seasonal malaria chemoprevention in northern Mozambique: a cost-effectiveness analysis.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Survival analysis of under-five mortality predictors: evidence from the 2011 and 2022/23 mozambique demographic and health surveys.BMC public health · 2026Article
- Agent-based simulation of seasonal malaria chemoprevention strategy in Southern Tanzania: comparing dihydroartemisinin-piperaquine with or without primaquine.Malaria journal · 2026Article
- The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria is endemic in Mozambique and one of the leading causes of death in children under 5 years old. In 2020 the country adopted the WHO-recommended seasonal malaria chemoprevention (SMC) strategy and delivered the intervention in all 23 districts of Nampula province between January and April 2023. The aim of this study is to estimate the cost-effectiveness of SMC in Nampula, Mozambique.
methodsFinancial cost of implementing SMC were estimated from a limited health care provider perspective for the year 2023 in US$. Data on resource use of the SMC implementation was assessed from Malaria Consortium records. The number of eligible and treated children was collected from surveys after cycle 4. The number of malaria cases, deaths and Disability Adjusted Life-Years (DALYs) averted were estimated based on data from Global Burden of Disease 2019, Malaria Indicator Survey 2018, and National Malaria Control Programme. Incremental cost-effectiveness ratios (ICERs) were estimated, and sensitivity analyses were used to test the robustness of the ICERs.
resultsThe total financial cost of SMC implementation in Nampula province in 2023 was estimated to be $7,871,361.72. The study estimated a cost per targeted child of $6.05 and a cost per child who received full 3-day course of sulfadoxine-pyrimethamine in combination with amodiaquine (SPAQ) of $7.92. Furthermore, the cost per household with eligible children visited by a community distributor was $7.65; the cost per child who received day 1 SPAQ was $7.85 and the cost per child who received day 1 SPAQ by community distributor adhering to directly observed treatment was $8.50. In addition, the estimated cost was $93.50 per malaria case averted, $3286.59 per malaria death averted, and $130.16 per DALY averted. The ICERs were robust to a variety of alternative assumptions on costs and benefit estimates. Finally, $1,726,189.63 could have been saved if no ineligible children (60-119 months old) were treated through the programme.
conclusionsIn line with existing evidence from other African countries, SMC is found to be cost-effective in Mozambique. SMC is a beneficial prevention strategy to improve under-five health in the country, at a relatively low-cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.